AI & Radiomics for Stratification of Lung Nodules After Radically Treated Cancer

Launched by ROYAL MARSDEN NHS FOUNDATION TRUST · May 10, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how artificial intelligence and advanced imaging techniques, called radiomics, can help doctors better understand new lung nodules in patients who have previously been treated for cancer. The goal is to determine whether these new nodules are benign (non-cancerous) or indicate a return of cancer, which can be crucial for deciding the best treatment options for patients.

To participate in the trial, individuals should be between the ages of 65 and 74 and have had a previous solid organ cancer treated with a curative intent within the last 10 years. They should have a new lung nodule that has been confirmed through imaging and meets specific size and stability criteria. Participants can expect to undergo imaging tests and possibly additional evaluations to help doctors learn more about their lung nodules. This research could lead to better ways to identify and manage lung nodules in cancer survivors, ultimately improving care and outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Confirmed history of previous radically or curative-intent treated solid organ cancer within 10 years of new index CT thoracic scan demonstrating a new pulmonary nodule and either of the following:
• • Biopsy confirming previous malignancy with MDT consensus and successful cancer resolution/remission following anti-cancer treatment on interval imaging or blood assay analysis
• • Where biopsy was not possible/confirmed for previous malignancy, MDT consensus outcome confirming cancer (+/- calculated Herder score \>80% if applicable) and decision to treat as malignancy with subsequent resolution/remission following anti-cancer treatment on interval imaging or blood assay analysis
• * Radical treatment for previous cancer defined as either of the following:
• • Surgical resection
• • Radical radiotherapy or stereotactic beam radiotherapy
• • Radical chemotherapy
• • Radical chemo-radiotherapy
• • Multi-modality treatment with any of the above
• • New pulmonary nodule ground truth known
• • Scan data showing 2-year stability (based on diameter or volumetry) or resolution in cases of benign disease
• • Scan data showing progressive nodule enlargement or increase in nodule number on interval imaging with MDT consensus (+/- PET with Herder score \>80% if applicable) determining metastatic disease or new primary malignancy
• • Biopsy sampling confirming benign disease or malignancy and in cases of malignancy, metastasis or new primary lung cancer
• • CT scan slice thickness ≤ 2.5mm
• • Nodule size ≥ 5mm
• Exclusion Criteria:
• • CT Imaging \> 10 years old
• • Non-solid haematological malignancies including leukaemia
• • Cases of radically treated primary cancer disease with early oligometastatic recurrence treated radically